Skip to main content
Clinical Trials/ITMCTR2100004596
ITMCTR2100004596
Recruiting
Phase 4

Efficacy and safety of Qianlieshutong capsule in the treatment of type III prostatitis (TCM syndrome of damp-heat and blood-stasis obstruction): a multicenter, randomized, double-blind, single simulation, positive drug parallel controlled clinical trial

Beijing Hospital0 sitesTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Beijing Hospital
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
Male

Investigators

Sponsor
Beijing Hospital

Eligibility Criteria

Inclusion Criteria

  • 1\. The diagnosis criterias of type III prostatitis are met;
  • 2\. The diagnosis criterias of TCM syndrome of damp\-heat and blood\-stasis obstruction are met;
  • 3\. Aged \>\= 18 and \<\= 50 years;
  • 4\. Chronic prostatitis symptom index (NIH CPSI) is more than 10, and pain score was \>\= 4;
  • 5\. Patients sign informed consent voluntarily.

Exclusion Criteria

  • 1\. Patients have weak waist and knees and are afraid of cold;
  • 2\. Patients diagnosed of benign prostatic hyperplasia, acute urinary retention, urethral stricture, epididymitis, seminal vesicle inflammation, severe neurosis, sexually transmitted diseases, bladder tumor, prostate cancer, and urinary male reproductive system tuberculosis;
  • 3\. Patients with pain diseases of lower abdomen, perineum, lumbosacral and other parts caused by non prostatitis;
  • 4\. Patients with severe cardiovascular, cerebrovascular, liver and kidney, endocrine system, hematopoietic system, mental and nervous system and other primary diseases, liver function ALT and / or AST were 1\.5 times higher than the upper limit of normal value, and renal function (CR) was greater than the upper limit of normal value;
  • 5\. Suspected or confirmed history of alcohol and drug abuse;
  • 6\. Urinary tract infection;
  • 7\. Refractory patients treated with a \- blockers;
  • 8\. Postural hypotension patients;
  • 9\. Allergic to the trial drug and its components;
  • 10\. Patients who had pelvic surgery within 3 months;

Outcomes

Primary Outcomes

Not specified

Similar Trials